TMCI
Treace Medical Concepts, Inc. · Healthcare
1.45
2.84%(+0.04)
Market Closed1.46
0.69%(+0.01)
After HoursLast Updated: — ET
52W L: $1.1752W H: $8.13
$1.45
CHG-0.02 (-1.36%)
H$1.66
L$1.18
VOL13M
TMCI (1h)
Treace Medical Concepts, Inc. · Healthcare
Treace Medical Concepts (NASDAQ: TMCI) management told investors it is entering what it called a "transformational phase," expanding beyond its historical Lapiplasty focus to become a broader "comprehensive bunion solutions company." On the company's fourth quarter and full-year 2025 earnings call, executives emphasized accelerating procedure volume growth and increasing "wallet share" within its customer base, while
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025.
PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Las Vegas, Nevada from February 24-26, 2026.
First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025.
PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
Hair Mark
officer: Chief Financial Officer
100,000 SH @ $0.00
2026-04-01
Elder Scot Michael
officer: Chief Legl & Comp Off, CorpSec
175 SH @ $0.00
2026-03-08
Elder Scot Michael
officer: Chief Legl & Comp Off, CorpSec
1,675 SH @ $0.00
2026-03-10
Scanlan Sean F.
officer: Chief Innovation Officer
401 SH @ $0.00
2026-03-08
Scanlan Sean F.
officer: Chief Innovation Officer
1,396 SH @ $0.00
2026-03-10
Treace John T.
director, 10 percent owner, officer: Chief Executive Officer
2,062 SH @ $0.00
2026-03-08
Treace John T.
director, 10 percent owner, officer: Chief Executive Officer
5,021 SH @ $0.00
2026-03-10
Hair Mark
officer: Chief Financial Officer
964 SH @ $0.00
2026-03-08